Abstract: Objective To assess the effect and safety of nicotinic acid and nicotinamide in treatment of hyperphosphatemia in dialysis patients by meta analysis. Methods Cochrane Library, PubMed, EMbase, CNKI, Wanfang Database and Weipu Database were used to do literature search on clinical trials studies in the treatment of hyperphosphatemia in dialysis patients by nicotinic acid or nicotinamide. After quality assessments and data extractions, all clinical trials accorded with standard were given a Mata analysis. Results A total of 328 maintenance dialysis patients (13 in peritoneal dialysis and the rest of patients in hemodialysis) in the 13 reports were analyzed. The results of Meta analysis showed that the level of serum phosphorus and calcium-phosphorus product decreased significantly after the treatment of nicotinic acid and nicotinamide, and there was no statistically difference in serum calcium, iPTH , platelet count between the treatment (or post-treatment) group and the control (or pre-treatment) group. Conclusion The current limited evidence suggests that nicotinic acid and nicotinamide are effective and safe in controlling serum phosphorus in dialysis patients. Because of the limits of the sample and quality of included studies, this conclusion has to be verified with more strictly desigened large clinical trials.

Key words: nicotinic acid, nicotinamide, maintenance dialysis, hyperphosphatemia, meta analysis